EP
AKBA icon

Eversept Partners’s Akebia Therapeutics AKBA Stock Holding History

Eversept Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Buy
+427,095
New +$508K 0.03% 114

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Eversept Partners's AKBA Position: Q2 2026 in Review

Eversept Partners opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 427,095 shares worth $487K. The stake represents 0.03% of the portfolio and ranks #114 among its holdings.

171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Eversept Partners held 427,095 shares of Akebia Therapeutics worth $487K as of Q2 2026.
  • Akebia Therapeutics was a new Eversept Partners position in Q2 2026.
  • Akebia Therapeutics made up 0.03% of Eversept Partners's portfolio in Q2 2026, its #114 holding.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.